Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.

Although Bruton's tyrosine kinase (BTK) has been recognized as a validated drug target for the treatment of B-cell malignances, the emergence of clinical resistance to the first-generation covalent BTK inhibitors is becoming a serious concern. As a part of our effort to develop noncovalent BTK inhibitors, a series of novel pyrrolopyrimidines was identified as noncovalent inhibitors of both the wild-type and C481S mutant BTKs. Subsequent lead optimization led to the identification of an orally available, potent, and selective BTK inhibitor 13f (AS-1763) as a next-generation noncovalent BTK inhibitor. With significant efficacies in vivo tumor xenograft models, AS-1763 has advanced to phase 1 clinical trials.

[1]  Y. Miao,et al.  Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies , 2021, Journal of Hematology & Oncology.

[2]  T. Kipps,et al.  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study , 2019, Leukemia.

[3]  M. Sawa,et al.  Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis. , 2018, Journal of medicinal chemistry.

[4]  B. Brandhuber,et al.  LOXO‐305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors: CLL‐200 , 2018, Clinical Lymphoma Myeloma and Leukemia.

[5]  R. Hendriks,et al.  Role of Bruton’s tyrosine kinase in B cells and malignancies , 2018, Molecular Cancer.

[6]  Adam R. Johnson,et al.  Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. , 2018, Journal of medicinal chemistry.

[7]  M. Sawa,et al.  Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[8]  K. F. Morgan,et al.  Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. , 2016, Chemical reviews.

[9]  A. Kuglstatter,et al.  Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. , 2015, Journal of medicinal chemistry.

[10]  M. Davids,et al.  Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. , 2014, Future oncology.

[11]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[12]  Y. Liu,et al.  Bruton's Tyrosine Kinase: Structure and Functions, Expression and , 2013 .

[13]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[14]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[15]  P. Čapek,et al.  Aqueous-phase suzuki-miyaura cross-coupling reactions of free halopurine bases , 2006 .

[16]  A. Satterthwaite,et al.  Btk function in B cell development and response. , 1998, Seminars in immunology.